LENZ Therapeutics (LENZ) Revenue & Revenue Breakdown
LENZ Therapeutics Revenue Highlights
Latest Revenue (Y)
$19.09M
Latest Revenue (Q)
$1.90M
Main Segment (Y)
License
LENZ Therapeutics Revenue by Period
LENZ Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $19.09M | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $15.00M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
LENZ Therapeutics generated $19.09M in revenue during NA 2025, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
LENZ Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $1.90M | 19.71% |
| 2025-12-31 | $1.59M | -87.30% |
| 2025-09-30 | $12.50M | 150.00% |
| 2025-06-30 | $5.00M | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
LENZ Therapeutics generated $1.90M in revenue during Q1 2026, up 19.71% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
LENZ Therapeutics Revenue Breakdown
LENZ Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 |
|---|---|
| Product | $1.59M |
| License | $17.50M |
Latest
LENZ Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: License (91.68%), and Product (8.32%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|---|---|---|---|
| Product | $1.65M | - | - | - |
| License | $250.00K | $12.50M | $5.00M | - |
| Reportable Segment | - | - | - | $5.00M |
Latest
LENZ Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Product (86.85%), and License (13.15%).
LENZ Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| GERN | Geron | $183.88M | $47.23M |
| SPRY | ARS Pharmaceuticals | $84.28M | $22.68M |
| MRVI | Maravai LifeSciences | $49.87M | $65.84M |
| NBTX | Nanobiotix | $30.06M | $30.06M |
| LENZ | LENZ Therapeutics | $19.09M | $1.90M |
| ABUS | Arbutus Biopharma | $14.08M | $179.13M |
| PRME | Prime Medicine | $4.63M | - |
| RZLT | Rezolute | - | - |
| SVRA | Savara | - | - |
| GHRS | GH Research | - | $80.00K |
| TYRA | Tyra Biosciences | - | - |